About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Our research group is a multidisciplinary team with clinical researchers from Orthopedic Surgery and Traumatology Service dedicated to preclinical translational research and members with different backgrounds in the field of biomedicine, biochemistry, biotechnology and biology from the Laboratory for the Development of Cell Therapies from the Banc de Sang i Teixits. The mission of this group is to develop cell and tissue-based therapies in the field of regenerative medicine. They are focused in design, conduct and transform preclinical efforts into clinical trials mainly in bone regeneration that could be used in different indications. The team holds a high degree of knowledge and translational experience thanks to several years working in the field and have also established successful collaboration with partners from different fields.
This research line seeks to promote bone regeneration using advanced cell therapy. Our alliance between biologists, engineers and clinical researchers enables us to develop new tissue engineering products that after thorough evaluation in the scopes of basic research and preclinical testing can then be applied in the human clinical setting.
Current Studies:
1. Autologous cell therapy with adult stem cells for osteonecrosis of the femoral head.
Osteonecrosis Clinical phase I-II study: We are currently conducting a comparative study between a product developed by our research group of advanced cell therapy in the context of osteonecrosis of the femoral head precollapse stage. It is a pioneering study at a national and international level by assessing the bone regenerative capability of this product compared to the classical treatment of core decompression.
2. Treatment of femoral head osteonecrosis with advanced cell therapy and biomaterials in an experimental sheep model.
Osteonecrosis preclinical study: We are evaluating mesenchymal stem cells expanded ex-vivo associated with different scaffolds and BMP in osteonecrosis of the femoral head in an ovine model. We are evaluating the different osteoconductive, osteoinductive and osteogenerative components to optimize the best biologic for the treatment of femoral head necrosis.
3. Experimental study of "in vivo" expanded adult stem cell therapy .
Critical size defect preclinical study: We are evaluating mesenchymal stem cells expanded ex-vivo in a critical segmental defect in an ovine model.
IP: Màrius Aguirre Canyadell, Roberto Vélez Villa
Research on degenerative hip pathology, bone necrosis, joint prostheses and walking disorders.
IP: Alejandro Hernández Martínez
Research on wrist and hand pathology with special attention to joint biomechanics.
IP: Alejandro Lluch Bergadá
The creation of hybrid digital-human interaction spaces between avatars and people offers new opportunities for personalized medicine
